Inhibikase Therapeutics Stock Alpha and Beta Analysis
| IKT Stock | USD 2.34 0.03 1.30% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Inhibikase Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Inhibikase Therapeutics over a specified time horizon. Remember, high Inhibikase Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Inhibikase Therapeutics' market risk premium analysis include:
Beta 1.86 | Alpha 0.72 | Risk 6.61 | Sharpe Ratio 0.16 | Expected Return 1.05 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Inhibikase |
Inhibikase Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Inhibikase Therapeutics market risk premium is the additional return an investor will receive from holding Inhibikase Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Inhibikase Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Inhibikase Therapeutics' performance over market.| α | 0.72 | β | 1.86 |
Inhibikase Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Inhibikase Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Inhibikase Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Inhibikase Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Inhibikase Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Inhibikase Therapeutics shares will generate the highest return on investment. By understating and applying Inhibikase Therapeutics stock market price indicators, traders can identify Inhibikase Therapeutics position entry and exit signals to maximize returns.
Inhibikase Therapeutics Return and Market Media
The median price of Inhibikase Therapeutics for the period between Wed, Aug 28, 2024 and Tue, Nov 26, 2024 is 1.45 with a coefficient of variation of 33.88. The daily time series for the period is distributed with a sample standard deviation of 0.61, arithmetic mean of 1.79, and mean deviation of 0.56. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Huawei spa rieenie na pestovanie talentov v oblasti IKT a vstavn centrum inteligentnho arelu univerzity | 09/24/2024 |
2 | Why Inhibikase Therapeutics Stock Is Up 50 percent Today | 10/09/2024 |
3 | Spolonos Huawei predstavila na GITEX GLOBAL 2024 vznamn lnok s nzvom Digitlna dividenda - vyspelos IKT podporuje ekonomick rast | 10/18/2024 |
4 | Insider Trading | 10/21/2024 |
5 | Inhibikase therapeutics director Kush Arvind buys 198,650 in stock | 10/23/2024 |
6 | Director Arvind Kush Acquires 145,000 Shares of Inhibikase Therapeutics Inc | 10/24/2024 |
7 | This Cytokinetics Analyst Begins Coverage On A Bullish Note Here Are Top 5 Initiations For Friday | 11/08/2024 |
8 | Inhibikase Potential To Improve Current Treatment Options For PAH Patients - Seeking Alpha | 11/19/2024 |
About Inhibikase Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Inhibikase or other stocks. Alpha measures the amount that position in Inhibikase Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 (projected) | Payables Turnover | 0.00584 | 21.06 | 22.11 | Days Of Inventory On Hand | 60.7K | 54.6K | 57.3K |
Inhibikase Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Inhibikase Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Inhibikase Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Inhibikase Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Inhibikase Therapeutics. Please utilize our Beneish M Score to check the likelihood of Inhibikase Therapeutics' management manipulating its earnings.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 29th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Inhibikase Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Inhibikase Stock Analysis
When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.